These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28583265)

  • 1. Use of the basophil activation test in monitoring clinical tolerance after desensitization to brentuximab vedotin.
    de la Varga Martínez R; Gutiérrez Fernández D; Áñez GA; Foncubierta Fernández A; Andrés García JA; Medina Varo F
    Ann Allergy Asthma Immunol; 2017 Jun; 118(6):745-747. PubMed ID: 28583265
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful desensitization to brentuximab vedotin after hypersensitivity reaction.
    Story SK; Petrov AA; Geskin LJ
    J Drugs Dermatol; 2014 Jun; 13(6):749-51. PubMed ID: 24918568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.
    DeVita MD; Evens AM; Rosen ST; Greenberger PA; Petrich AM
    J Natl Compr Canc Netw; 2014 Apr; 12(4):465-71. PubMed ID: 24717566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
    Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
    Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Desensitization to Brentuximab After Anaphylactic Shock.
    Görgülü B; Toprak SK; Bavbek S
    J Investig Allergol Clin Immunol; 2018 Oct; 28(5):352-354. PubMed ID: 30350795
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.
    V Villarreal-Gonzalez R; N Gonzalez-Diaz S; E de Lira-Quezada C; Gómez-Almaguer D; Gómez-De León A; Acuña-Ortega N
    J Oncol Pharm Pract; 2021 Mar; 27(2):505-508. PubMed ID: 32686619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unsuccessful Desensitization to Paclitaxel in a Patient With High Basophil Sensitivity.
    Kopač P; Koren A; Jošt M; Mangaroski D; Lainščak M; Korošec P
    J Investig Allergol Clin Immunol; 2021 Jun; 31(3):263-265. PubMed ID: 32732178
    [No Abstract]   [Full Text] [Related]  

  • 8. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful desensitization to brentuximab vedotin after anaphylaxis.
    O'Connell AE; Lee JP; Yee C; Kesselheim J; Dioun A
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e73-5. PubMed ID: 24373790
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
    Perrot A; Monjanel H; Bouabdallah R; Quittet P; Sarkozy C; Bernard M; Stamatoullas A; Borel C; Bouabdallah K; Nicolas-Virelizier E; Fournier M; Morschhauser F; Brice P;
    Haematologica; 2016 Apr; 101(4):466-73. PubMed ID: 26768687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaphylactic shock due to brentuximab-vendotin confirmed by skin test and in vitro tests.
    Noguerado-Mellado B; Rojas-Pérez-Ezquerra P; Sáenz de Santa María García M; Rodriguez-Macías G; Tornero P; Bartolomé B
    J Allergy Clin Immunol Pract; 2017; 5(5):1427-1429. PubMed ID: 28634100
    [No Abstract]   [Full Text] [Related]  

  • 12. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
    Oak E; Bartlett NL
    Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
    Fizesan M; Boin C; Aujoulat O; Newinger G; Ghergus D; Watier H; Lustig H; Ojeda-Uribe M
    J Oncol Pharm Pract; 2016 Feb; 22(1):188-92. PubMed ID: 25586990
    [No Abstract]   [Full Text] [Related]  

  • 14. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
    Chen R; Chen B
    Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin.
    Wagner-Johnston ND; Bartlett NL; Cashen A; Berger JR
    Leuk Lymphoma; 2012 Nov; 53(11):2283-6. PubMed ID: 22424602
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization.
    González-de-Olano D; Morgado JM; Juárez-Guerrero R; Sánchez-Muñoz L; Letellez-Fernández J; Malón-Giménez D; Castells MC
    J Allergy Clin Immunol Pract; 2016; 4(2):338-40. PubMed ID: 26725157
    [No Abstract]   [Full Text] [Related]  

  • 19. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.